Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D

Damian Garde

Antibiotics biotech Therapeutics executed a $ 92.3 million IPO, pricing well below its projected range but scraping together the funds it needs to start a Phase III study for its lead drug.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS